DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

RTTNews | 606天前
Stocktwits
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line

(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

Charles River Research Models & Services (RMS) sales and marketing teams will collaborate with DURECT to jointly market and commercialize the ALZET product line to existing and new customers over a multi-year period.

Charles River RMS will provide dedicated marketing resources and collaborate with DURECT to develop and roll out a broad range of sales and marketing initiatives for ALZET.

DURECT will remain responsible for manufacturing, marketing support, order fulfillment and customer billing.

标签: DRRX CRL
Stocktwits
read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 450天前
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.
RTTNews | 904天前
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1185天前
DURECT Appoints Timothy Papp As New CFO

DURECT Appoints Timothy Papp As New CFO

Biopharmaceutical company DURECT Corp. (DRRX) announced Tuesday the appointment of Timothy Papp as its Chief Financial Officer. Papp brings over 25 years of corporate finance experience to DURECT, including 15 years in the Biopharma sector.
RTTNews | 1214天前
Swiss Market Settles Moderately Lower

Swiss Market Settles Moderately Lower

The Switzerland market ended weak on Friday, in line with markets across Europe, as investors chose to trim down positions at several counters, continuing to react to earnings updates and assessing the developments on the trade front.
RTTNews | 4小时16分钟前
European Markets Close Weak After Cautious Session

European Markets Close Weak After Cautious Session

European markets closed weak on Friday, as investors reacted to a slew of earnings updates, regional economic data, and continued to assess the recent policy announcements from major central banks, and the developments on the trade front.
RTTNews | 4小时40分钟前
工具
经济日历
市场时间
利率
节假日日历
外汇市场
外汇波动率
外汇相关性
外汇新闻
外汇分析
COT数据
流动性
外汇计算器
外汇热力图
经济指标
社区
社区
系统
最受欢迎的系统
策略
竞赛
外汇图表
外汇情绪
展望指标
评论
经纪人
自营交易公司
VPS服务
信号提供者
EA编程服务
联盟计划
PAMM经纪人服务
返利计划服务
交易平台
专家顾问
加密货币交易所
交易课程
经纪人
外汇点差
外汇经纪商报价
外汇经纪商掉期
外汇经纪商交易量
外汇经纪商促销
新闻稿
平台
小工具
功能
API
RSS
Stock Portfolio
Affiliate Software
高级图表
支持
常见问题
帮助
联系我们
报告一个错误！
关于我们
博客
© 2025 Myfxbook Ltd. All Rights Reserved.
高风险警告：外汇交易具有高风险，可能不适合所有投资者。 杠杆创造了额外的风险和损失风险。 在您决定进行外汇交易之前，仔细考虑您的投资目标、经验水平和风险承受能力。 您可能会损失部分或全部的初始投资。不要投资您无法承受损失的钱。 对自己进行与外汇交易有关的风险教育，如果您有任何问题，请向独立的财务或税务顾问咨询。 任何数据和信息都是"按原样"提供的，仅仅是为了提供信息，并不打算用于交易目的或建议。 过去的业绩并不代表未来的结果。